Vycor Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:40 pm EST
Share
Vycor Medical, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.308593 million compared to USD 0.309969 million a year ago. Net loss was USD 0.051904 million compared to USD 0.114807 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago.
For the nine months, sales was USD 1.15 million compared to USD 0.951725 million a year ago. Net income was USD 0.023364 million compared to net loss of USD 0.288369 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.02 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
